Product Description
Reference Standards &Impurity
AI Product Description
*The following content is generated by AI and is for reference only.
Riociguat is a novel oral medication classified as a soluble guanylate cyclase (sGC) stimulator, designed to treat specific cardiovascular conditions. Its molecular formula is C23H24N6O2S, and it carries the CAS registry number 157902-78-0. This compound functions by directly activating sGC in vascular smooth muscle cells, independent of nitric oxide presence. Upon activation, sGC catalyzes the conversion of guanosine triphosphate (GTP) into cyclic guanosine monophosphate (cGMP). Elevated cGMP levels trigger a cascade of intracellular events leading to vasodilation, which reduces pulmonary vascular resistance and improves blood flow through the lungs.
The primary clinical indication for Riociguat is chronic thromboembolic pulmonary hypertension (CTEPH) in patients who are not candidates for curative pulmonary endarterectomy surgery or have persistent or recurrent disease after such procedures. Additionally, it is approved for the treatment of pulmonary arterial hypertension (PAH), specifically World Health Organization Group 1 PAH, to improve exercise capacity and delay clinical worsening. By enhancing the nitric oxide-cGMP pathway, Riociguat addresses the underlying pathophysiology of these diseases, where endothelial dysfunction leads to vasoconstriction and vascular remodeling.
Unlike phosphodiesterase-5 inhibitors, which prevent the breakdown of cGMP, Riociguat stimulates its production directly, offering a distinct mechanism of action that can be effective even when nitric oxide signaling is impaired. The drug is administered orally, typically starting at a low dose and titrated up based on patient tolerance and hemodynamic response. Common side effects include headache, hypotension, dizziness, nausea, and dyspepsia. Clinicians must carefully monitor blood pressure and avoid concurrent use with nitrates or other potent vasodilators due to the risk of severe hypotension. Furthermore, Riociguat is contraindicated during pregnancy because animal studies have shown teratogenic effects. As a targeted therapy, Riociguat represents a significant advancement in managing complex pulmonary hypertension disorders, providing improved quality of life and survival outcomes for patients with limited therapeutic options. Its unique pharmacological profile continues to make it a cornerstone in modern cardiopulmonary medicine.